Economic aspects of medical erectile dysfunction therapies
Authors:
- 1 March 2002
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 3 (3) , 257-263
Abstract
The introduction of safe and effective oral therapies has changed the significance of erectile dysfunction (ED) forever. Seldom has a new drug changed the landscape of pharmacotherapy in so many ways as sildenafil (Viagra™, Pfizer). This article highlights the various oral, intracavernosal and intraurethral therapies currently available for ED and evaluates the socio-economic impact of each method.Keywords
This publication has 17 references indexed in Scilit:
- Erectile dysfunction in general medicine practice: prevalence and clinical correlatesInternational Journal Of Impotence Research, 2000
- Clinical safety of oral sildenafil citrate (VIAGRATM) in the treatment of erectile dysfunctionInternational Journal Of Impotence Research, 1998
- Treatment of Men with Erectile Dysfunction with Transurethral AlprostadilNew England Journal of Medicine, 1997
- A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadilUrology, 1996
- Efficacy and Safety of Intracavernosal Alprostadil in Men with Erectile DysfunctionNew England Journal of Medicine, 1996
- Effect of Apomorphine on Penile Tumescence in Men with Psychogenic ImpotenceJournal of Urology, 1991
- Incidence and prevalence of the sexual dysfunctions: A critical review of the empirical literatureArchives of Sexual Behavior, 1990
- Prostaglandin 15‐hydroxydehydrogenase Activity in Human Penile Corpora Cavernosa and its Significance in Prostaglandin‐mediated Penile ErectionBritish Journal of Urology, 1989
- Intracavernous Injection of Prostaglandin E1 for the Treatment of Erectile ImpotenceJournal of Urology, 1989
- Auto-Injection of the Corpus Cavernosum with a Vasoactive Drug Combination for Vasculogenic ImpotenceJournal of Urology, 1985